Dislog Group continues its expansion in the medical sector by signing a memorandum of understanding to acquire 70% of the shares in Afrobiomedic, a key player in the field of implantable cardiology devices in Morocco. This move is part of the group's external growth strategy (M&A) and aims to strengthen its healthcare division.
Established in 2009, Afrobiomedic focuses on importing and distributing medical devices for interventional cardiology, structural cardiology, and electrophysiology, extending its reach into vascular interventional neuroradiology as well. By maintaining exclusive agreements with renowned global manufacturers, the firm provides state-of-the-art equipment compliant with ISO 13485 regulations, thus guaranteeing superior quality products for healthcare providers in Morocco.
Driss Nasr, who founded and remains the exclusive owner of Afrobiomedic, will keep 30% ownership stake and will stay at the helm to steer the company’s expansion within Morocco and across Africa. Partnering with Dislog Group will expedite Afrobiomedic’s growth through harnessing the synergistic effects and manufacturing strengths of the group.
The Dislog Group, having firmly established itself within the pharmaceutical sector and medical device field, further bolsters its healthcare arm. This division encompasses various niche enterprises like Megaflex, Kosmopharm, Steripharma, Somapharma, Africare, and Dislog Santé. The structure of this unit revolves around three key areas: pharmaceuticals, medical devices, and dermatocosmetics, forming an extensive continuum spanning medication production all the way through to specialized equipment delivery.
This deal is still contingent upon the Competition Council's approval.